Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Top Global Pharma Daiichi Sankyo Extends Use of the Medidata Clinical Cloud to China



  Top Global Pharma Daiichi Sankyo Extends Use of the Medidata Clinical Cloud
  to China

 Leading Pharma Looks to Medidata Solutions to Bring Operational Efficiencies
                         to Clinical Trials in China

Business Wire

NEW YORK -- July 31, 2013

Daiichi Sankyo Co., Ltd., a top 20 pharmaceutical company headquartered in
Japan, is expanding its use of Medidata Solutions’ (NASDAQ: MDSO) cloud-based
platform to support clinical trials conducted by its division in China. A
long-time Medidata customer, Daiichi Sankyo will bring Medidata’s
industry-leading applications for electronic data capture (EDC) and clinical
data management (CDM) and randomization and trial supply management (RTSM) to
its expanding clinical work in China. Daiichi Sankyo’s investment in the
Medidata Clinical Cloud™ for its China division is expected to streamline
trial activities, improve the efficiency of data capture and increase the
productivity of site users and clinical monitors.

By adopting Medidata’s industry-leading data capture, management and reporting
solution (Medidata Rave^®) in conjunction with its agile randomization and
trial supply management solution (Medidata Balance^®), Daiichi Sankyo will
have access to a single cloud-based platform that provides a unified
environment in which site staff will conduct patient randomization, supply
dispensing and clinical data capture, as well as enabling collaboration and
insightful metrics visibility for the whole research team.

Daiichi Sankyo chose the Medidata platform for its expansion in China based on
the improvements realized from its large-scale use of the Medidata platform
since 2005. Medidata Services Partner Tigermed, a leading contract research
organization (CRO), was involved in the selection and implementation of the
Medidata platform for the China-based work.

“Medidata and Daiichi Sankyo have a long and fruitful relationship as
collaborators, and we are delighted they have asked us to provide the
efficient, effective and modern infrastructure needed for their clinical
development programs in China,” said Glen de Vries, president, Medidata
Solutions. “Organizations like Daiichi Sankyo that leverage innovative
clinical technologies will be the leaders in bringing new life-enhancing
treatments to market.”

Connect with Medidata:

  * Tweet this: With success in Japanese trials, Daiichi Sankyo extends use of
    Medidata Clinical Cloud to #China trials http://bit.ly/13wCHfE
  * Read our blog, Geeks Talk Clinical
  * Follow us on Twitter: @Medidata
  * Find us on LinkedIn

About Medidata Solutions

Medidata Solutions is the leading global provider of cloud-based solutions for
clinical research in life sciences, transforming clinical development through
its advanced applications and intelligent data analytics. The Medidata
Clinical Cloud™ brings new levels of productivity and quality to the clinical
testing of promising medical treatments, from study design and planning
through execution, management and reporting. We are committed to advancing the
competitive and scientific goals of our global customers, which include over
90% of the top 25 global pharmaceutical companies; innovative biotech,
diagnostic and device firms; leading academic medical centers; and contract
research organizations.

Contact:

Medidata Solutions
Gail Janowitz, 212-918-1792
gjanowitz@mdsol.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement